Y-Biologics

Y-Biologics is developing global new drugs through optimized partnerships, considering the characteristics of two platform technologies (Ymax®-ABL, ALiCE) and new antibody drug production lines to establish a business model.The company conducts joint development and investment through strategic alliances with partners, providing various business opportunities such as research services and joint ventures. From the construction of South Korea's first unique human antibody library to the development of global immuno-oncology antibody drugs, the company has successfully built a unique human antibody library Y-max ABL and a new bispecific antibody platform technology ALiCE. Based on this, the company has developed various antibody drugs and become a global leading company. The company is making every effort to advance into the immunochemistry drug market.